Health Data Analytics Institute (HDAI) deploys innovative use of LLMs for summarizing and supporting patient preferences at a leading cancer center

HDAI collaborates with Dana-Farber to help clinicians improve goal-concordant care for patients with serious illness

BOSTON, Oct. 20, 2025 /PRNewswire/ — An innovative new protocol called Better Real-time Information on Documentation of Goals of care for Engagement in Serious Illness Communication (BRIDGE-SIC) is being launched today at Dana-Farber Cancer Institute. BRIDGE-SIC uses Health Data Analytics Institute (HDAI) large language models (LLMs) to extract and summarize patients’ goals of care conversations and their risk stratification tools for patient selection. The AI summaries identify and summarize prior goals of care conversations documented in patients’ medical records and share them with inpatient and outpatient clinicians when patients with cancer are admitted to the hospital. The hope is that such summaries will prompt awareness of patients’ preferences and communication between patients’ inpatient and outpatient teams, improving patient-centered care when patients are admitted to the hospital. This program builds from two previous studies at Dana-Farber, focused on LLM prompt development and testing (see below). The study applies HDAI’s HealthVision AI-guided platform which provides comprehensive, real-time stratification capabilities and LLM-based synthesis technology, embedded right in the EHR for ease of access.

Charlotta Lindvall, MD, PhD Co-principal investigator

Chris Manz, MD Sponsor and co-principal investigator

BRIDGE-SIC is a pilot study to determine the accuracy and feasibility of applying LLMs to improve identification, summarization and communication around goals of care. Upon successful completion, a larger study will determine whether this intervention has an impact on the care that patients receive during and after hospitalization.

Christopher Manz, MD, is the sponsor-investigator and study Co-Principal Investigator. Dr. Manz is an Assistant Professor in Medical Oncology at Dana-Farber in the Gastrointestinal Cancer Center and Division of Population Sciences. He has experience implementing pragmatic clinical trials to improve serious illness conversations at the University of Pennsylvania Health System and Dana-Farber. Charlotta Lindvall, MD, PhD, is the Co-Principal Investigator. Dr. Lindvall is a palliative care physician and researcher at Dana-Farber and Harvard Medical School, in Boston. She leads a cross-disciplinary research team of physicians, nurses, and computer scientists to develop AI to extract patient-centered outcomes from clinical narratives and conversations, and has research experience applying LLMs to summarize SICs. She additionally serves as Senior Advisor to Clinical Informatics at Dana-Farber and as technical expert on AI for the National Quality Forum. Manuel Fanarjian, MD, is a palliative care physician and clinical informaticist at Dana-Farber, as well as an Instructor in Medicine at Harvard Medical School. He provides clinical informatics leadership, in concert with the hospital’s Information Services team.

Dr. Manz noted that, “Patients with cancer often receive care near the end-of-life that may not be beneficial or accordant with their preferences. Serious Illness Conversations (SIC) between patients and clinicians improve well-being and reduce aggressive care near the end-of-life by identifying and matching care to patient goals and preferences. Because SIC documentation is often buried in voluminous free-text EHRs, a key challenge in ensuring high-quality, goal-concordant care in acute hospitalization settings is effectively identifying and communicating patient preferences to clinical teams providing inpatient care. LLMs are helping us to drastically reduce the time and effort needed to search for documentation of these conversations.”

“We believe deeply in the goal of every patient having their wishes front and center,” said Dr. Lindvall. “We are on track to show that LLMs for real-time identification of Serious Illness Conversations work and represent a major breakthrough in our field.”

Dana-Farber has implemented HDAI’s HealthVision platform, viewable in the EHR, applying validated prediction models to stratify patients at highest risk of 90-day mortality for inclusion in the trial and a secure, performant LLM infrastructure that creates SIC summaries in seconds, not minutes. For eligible patients in the trial, these summaries are sent to the inpatient and outpatient clinical teams for patients being admitted to the hospital.

“As I’ll share on the stage at HLTH this week, academic medical centers like Dana-Farber are home to some of the most advanced clinical research in the world, yet they often face significant challenges when trying to connect patients with palliative care resources – challenges rooted in care complexity, clinician time and fragmented data,” said Nassib Chamoun, founder and CEO of HDAI. “We are truly honored to be part of this important work that will pave the way for better care alignment with patients with serious illness and as an exemplar for other institutions to emulate.”

The results will be compiled in early 2026 and presented at conferences and in publications by the Fall of next year.

About previous studies from this team
Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer.
Agaronnik ND, Davis J, Manz CR, Tulsky JA, Lindvall C.JCO Oncol Pract. 2025 Apr 10:OP2400992. doi: 10.1200/OP-24-00992.

Large Language Models to Identify Advance Care Planning in Patients With Advanced Cancer.
Agaronnik ND, Davis J, Manz CR, Tulsky JA, Lindvall C.J Pain Symptom Manage. 2025 Mar;69(3):243-250.e1. doi: 10.1016/j.jpainsymman.2024.11.016.

About Health Data Analytics Institute (HDAI)
HDAI is focused on addressing the US’s looming healthcare crisis with actionable, responsible AI tools that help improve care outcomes, financial results and clinician satisfaction for healthcare systems and value-based care organizations. HDAI’s HealthVision™ is software that combines hundreds of high-performing, pre-built predictive models with LLM-enabled chart summarizing capabilities and a powerful, cost-effective, scalable cloud computing platform. HealthVision is embedded in the EHR and provides AI-enabled, use-case specific, patient stratification in real-time across the continuum of care. These intelligent rosters make it easier to align scarce resources with the patients at the time they are most needed. At the patient level, HealthVision synthesizes hundreds of encounters into one-page AI Summaries that help clinicians quickly understand patient needs, replacing tedious, time-consuming searches. Recognized in the 2025 TIME Top 100 HealthTech companies list.

Media Contact: Carola Endicott, HDAI, 617-699-0725

SHARE

Facebook
Twitter
LinkedIn

Your privacy matters

We believe that an individual’s meaningful control over their own data is as valuable as the data itself. That’s why we are committed to protecting privacy at every turn.
We always:
  • Provide transparency about the information we collect and why we collect it
  • Comply with all applicable privacy rules and regulations
  • Delete personal data from our servers if an individual opts out
We never:
  • Sell data to third parties
  • Share data with third parties besides the primary, explicitly authorized institution
  • Collect data besides what is disclosed
  • Keep personal data for individuals who have opted out

We speak legalese only when we have to, but we do our best to keep it human. Provided below are the full versions of our Privacy Policy and Terms of Service. If you have any questions, don’t hesitate to contact us for clarification.

Raphael Cohen
VP AI and Engineering

With expertise in machine learning, cloud computing, and healthcare, Raphael translates complex technical challenges into practical healthcare solutions. He’s pioneered ML platforms to drive innovations in radiology, pathology, and anesthesia while simultaneously improving operational efficiency and scale. Outside of work, he’s an avid cyclist who regularly participates in the Pan-Mass Challenge, enjoys hiking the White Mountains, and is often found playing guitar. He received a BS in Computer Science and Applied Mathematics from Brandeis University.

Bob Scott
VP Security, Compliance, and IT Operations

Bob has 20 years experience enhancing IT systems and security programs in regulated companies.  He has worked with global enterprises down to 10-person start-ups.  He currently holds both CISSP and CCSP certificates from ISC2.  Bob’s professional passion is negotiating the sweet-spot between Security, Efficiency and Company Resources.  Personally, Bob is a land-locked boatsman who laments every day away from the water and an avid table-top gamer.  He received a BS in Microbiology from Cornell.

Summer Kramer
VP Clinical Programs

Summer is a clinical pharmacist with over 15 years of experience in the healthcare industry, including hospitals, payors, and start-ups. Summer has focused her career on clinical program development and healthcare analytics with a constant drive to improve patient outcomes.

Residing in the pacific northwest, Summer enjoys hiking, camping, sailing, and traveling. She received her PharmD from the University of New Mexico, College of Pharmacy.  

Kevin Sampson
VP Finance

Kevin is a CPA with 25 years of executive and managerial experience in accounting, corporate finance, and operations in a variety of industries including medical device, biotechnology, and pharmaceuticals.

By listening and connecting with people, Kevin understands that accurate timely information is vital for everyone in the healthcare system. He received a BS in Accounting and an MBA in Finance and Entrepreneurial Studies from Babson College.

Paul Manberg
VP Clinical and Regulatory Affairs

Paul is an innovative, pragmatic leader with over 40 years’ experience in the medical device and pharmaceutical industries. He has directed clinical trial programs and regulatory activities supporting the successful market introduction of numerous impactful products. He spends his leisure time on the Outer Banks of North Carolina, body surfing and fishing. He received a PhD in pharmacology from The University of North Carolina School of Medicine.

Scott Greenwald
Chief Scientist

With over 25 years’ experience in healthcare research and innovation, Scott is an unprecedented leader in his field, focusing on improved care for everyone. He is an author of over 10 US Patents and over 100 peer-reviewed abstracts and manuscripts. While he’s not immersed in research, you’ll find him playing a mean round of mini golf. He received a PhD in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology (HST).

Josh Gray VP Analytic Services

Josh has 30 years’ experience in healthcare, including The Advisory Board Company, athenahealth, and Boston Consulting Group. Across his career, he has used a wide range of conventional and unconventional data sources to understand and teach the keys to top performance among the nation’s most innovative health systems and physician groups. Josh enjoys music, hiking, traveling, and watching his daughter take part in synchronized skating competitions. He received an MBA from The Wharton School at the University of Pennsylvania and an undergraduate degree from Brown University.

Carola Endicott
VP Customer Engagement, Marketing

Carola has 30 years’ experience in healthcare, including HMOs, hospitals, and start-ups. Her knowledge and optimistic outlook in operations and leadership, and her passion for making healthcare workers’ lives easier is what drives her devotion to customer engagement. She received an EdM from Harvard University Graduate School of Education.

David Clain Chief Product Officer

David has vast experience with healthcare customers from his time at The Advisory Board Company and athenahealth. His expertise and passion for statistics, strategy, and innovative analytic insights is unrivaled, as is his devotion to the Duke Blue Devils. Looking for that “aha moment” of positive change is what drives him. He received a BA from Duke University.

Margie Ahearn
VP HR

Margie has 25 years of experience in HR leadership. An avid boater, Margie has received numerous awards for excellence in HR and is always looking for challenges to grow professionally and personally. She graduated with an MBA from Southern New Hampshire University.

Nassib Chamoun
Founder and CEO

Nassib is a data scientist, lover of logistical regression and a serial entrepreneur. Previously, he was Founder and CEO of Aspect Medical Systems, a Nasdaq traded company now owned by Medtronic. Outside of work, he enjoys hosting and honing his cooking skills – specializing in Middle Eastern and outdoor feasts. He received an MS from Boston University.

Phil Devlin
COO

Phil has 30 years of experience in executive leadership. Along his journey he’s made effective and profound change in science. Little known facts about him — he loves traveling with his family, he was in the MD Engineering program at Harvard Medical School and owns 15 patents. He received an MS from Northeastern University.

What guides our culture

1

We are driven to make a profound impact on US healthcare

2

We operate in the best interests of patients and those who serve them

3

We understand and protect patient privacy and health information security

4

We use data science to enhance, but never replace clinical expertise and judgment

5

We are committed to continuous learning and improvement

6

We bring rigor, discipline, and reliability to our work

7

We start with kindness, assuming good intent in others

8

We are committed to building a diverse, inclusive team where all employees feel welcomed and appreciated

9

We are committed to the well-being of our employees and their families

Our vision

We envision a healthcare system where decisions are routinely informed by personalized care profiles and predictive analytics, which will improve the health of individuals and populations.

Our mission

Deploy a versatile analytic platform that creates a shared understanding of quantified health risks to inform actions with the greatest potential to benefit patients.

Who we are

We collaborate with leading health systems and integrated delivery networks, value-based care and accountable care organizations, physician groups, and commercial payers to improve care delivery and population health while reducing costs and making efficient use of scarce clinical resources.

Phil Devlin
COO

Phil has 30 years of experience in executive leadership. Along his journey he’s made effective and profound change in science. Little known facts about him — he loves traveling with his family, he was in the MD Engineering program at Harvard Medical School and owns 15 patents. He received an MS from Northeastern University.